GOSS: Upcoming Regulatory Updates On Lead Program Will Drive Potential Rerating

Analysts have cut Gossamer Bio's $5.00 fair value estimate to $4.46 and now apply a higher 12.46% discount rate and a richer 104.9x future P/E, reflecting concerns around going concern risks, equity dilution from the debt exchange, and regulatory uncertainty around seralutinib, even as some still highlight its potential in pulmonary arterial hypertension.

Analyst Commentary

Street research around Gossamer Bio is split, with some analysts emphasizing upside tied to seralutinib's potential in pulmonary arterial hypertension and others focusing on funding risks, dilution, and regulatory uncertainty. For you as an investor, the key debate centers on whether the current valuation reflects these execution and financing challenges or still embeds high expectations for future success.

Bullish Takeaways

Bullish analysts see meaningful upside if seralutinib advances, pointing to expert views that the drug's inhaled PDGFR-targeting approach and focus on vascular remodeling could address a clear unmet need in pulmonary arterial hypertension.
Some remain constructive even with lower price targets, maintaining positive ratings and highlighting the possibility of a re-rating if upcoming CT FRI substudy data, Week 48 results, and future FDA interactions reduce regulatory uncertainty.
Supportive commentary links upside potential directly to successful execution on clinical milestones and regulatory discussions, arguing that current valuation may not fully reflect the drug's perceived approval likelihood among certain experts.
Positive views also recognize that the rich future P/E assumptions in some models are largely tied to long term growth optionality if seralutinib progresses as hoped.

Bearish Takeaways

Bearish analysts stress the "going concern" warning and question the company's ability to secure additional capital, which in their view creates enough uncertainty that a clear investment rating cannot be justified at this time.
Several research notes point to equity dilution from the 2027 note exchange, viewing the transaction as improving the balance sheet at the cost of existing shareholders, which weighs on valuation support.
Lowered price targets and more cautious ratings are tied to regulatory and execution risk around seralutinib, with at least one firm cutting the probability of success for pulmonary arterial hypertension from 70% to 50%, which directly reduces modeled value.
Overall, the cautious camp focuses on funding runway, dilution, and regulatory hurdles as key overhangs that could limit upside until there is clearer evidence on both capital access and clinical outcomes.

What's in the News

On April 8, 2026, Gossamer Bio received a notice from Nasdaq that its common stock did not meet the US$1.00 minimum bid price requirement for the prior 30 consecutive business days. This triggered a 180 day grace period until October 5, 2026, to regain compliance. (Source: Nasdaq notice as described in company disclosure)
The Nasdaq notice states that Gossamer Bio could receive an additional 180 day compliance period if it transfers to the Nasdaq Capital Market and meets all other initial listing standards. It may consider steps such as a reverse stock split, although there is no assurance that compliance will be regained. (Source: company disclosure)
On March 17, 2026, Gossamer Bio filed its Form 10 K for the year ended December 31, 2025. Auditor Ernst & Young LLP issued an unqualified opinion that included doubt about the company’s ability to continue as a going concern. (Source: Form 10 K)
Gossamer Bio was removed from the S&P Biotechnology Select Industry Index, which can affect index linked ownership and trading activity in the stock. (Source: index provider announcement)

Valuation Changes

Fair Value: The updated estimate has moved from $3.69 to $4.46 per share, reflecting a higher modeled valuation for the stock.
Discount Rate: The assumption has risen from 11.23% to 12.46%, indicating a higher required return being applied to future cash flows.
Revenue Growth: The long-term revenue growth assumption has shifted from 40.02% to 42.09%, implying slightly stronger projected top-line expansion in the model.
Net Profit Margin: The modeled net margin has moved from 13.97% to 9.78%, pointing to a more conservative view on future profitability in percentage terms.
Future P/E: The target future P/E multiple has increased from 70.41x to 104.90x, implying a richer earnings multiple assumption for potential future profitability.

0 views

Key Takeaways

Successful Phase III study enrollment and collaboration enhance market reach, promising revenue growth through potential positive efficacy results and expanded indications.
Anticipated first-in-class status and expanded dosing strategies could drive market adoption and earnings through competitive positioning and a broader patient base.
High R&D costs, regulatory risks, and reliance on clinical trial success could strain financial resources, impacting investor confidence and long-term financial sustainability.

Catalysts

About Gossamer Bio

A clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.What are the underlying business or industry changes driving this perspective?

The successful enrollment of the PROSERA Phase III study with a targeted patient population and significant interest from patients and physicians demonstrates alignment with clinical trial goals, which could potentially lead to positive efficacy results and subsequently drive future revenue growth.
The collaboration with Chiesi Group to enter a global registrational Phase III study for seralutinib in PH-ILD enhances the opportunity for expanded indications and market reach, potentially impacting revenue positively.
The anticipation of potential first-in-class treatment status for seralutinib, with observed safety and reverse remodeling effects, implies significant market adoption potential, which could improve net margins due to competitive product positioning.
The extensive global enrollment for PROSERA, with high interest from international markets, indicates potential for international revenue expansion, particularly in large PAH markets like Japan, where positive trial outcomes could lead to approvals and additional market penetration.
The expanded dosing strategy in the Phase III CIRANATA study to explore antifibrotic effects in PH-ILD aims to achieve differentiated clinical outcomes, potentially enabling a broader label claim and expanding the addressable market, thereby positively impacting earnings through an increased patient base.

Gossamer Bio Earnings and Revenue Growth

Gossamer Bio Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Gossamer Bio's revenue will grow by 42.1% annually over the next 3 years.
Analysts assume that profit margins will increase from -324.8% today to 9.8% in 3 years time.
Analysts expect earnings to reach $15.6 million (and earnings per share of $0.08) by about June 2029, up from -$180.4 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $349.6 million in earnings, and the most bearish expecting $-234.6 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 104.9x on those 2029 earnings, up from -0.3x today. This future PE is greater than the current PE for the US Biotechs industry at 16.2x.
Analysts expect the number of shares outstanding to grow by 3.22% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 12.46%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The reliance on forward-looking statements carries inherent uncertainties, raising concerns about the reliability of anticipated financial outcomes, which could impact investor confidence and overall revenue projections.
The company's involvement in global clinical trials increases regulatory and operational risks, which could delay product availability and impact both potential revenue streams and net margins.
The high R&D expenditures relative to current revenue generation, as indicated by the $38 million in R&D expenses versus $9.9 million in quarterly revenue, could strain financial resources, affecting earnings and profitability.
Dependency on the successful outcome of the PROSERA Phase III trial for seralutinib is risky, with negative or inconclusive results potentially causing substantial financial setbacks and reducing projected revenues.
Gossamer Bio's cash runway to the first half of 2027 necessitates careful financial management, as any deviation in trial success or collaboration milestones could lead to funding gaps affecting long-term financial sustainability and net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $4.46 for Gossamer Bio based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $15.0, and the most bearish reporting a price target of just $0.28.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $159.3 million, earnings will come to $15.6 million, and it would be trading on a PE ratio of 104.9x, assuming you use a discount rate of 12.5%.
Given the current share price of $0.2, the analyst price target of $4.46 is 95.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Gossamer Bio?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Phase III Trials And Global Collaborations Will Expand Treatment Horizons